Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Vujovic, Balsa (57021631300)"

Filter results by typing the first few letters
Now showing 1 - 7 of 7
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Clinical and epidemiological features of Guillain-Barré syndrome in the Western Balkans
    (2014)
    Peric, Stojan (35750481700)
    ;
    Milosevic, Vuk (24480195100)
    ;
    Berisavac, Ivana (6507392420)
    ;
    Stojiljkovic, Olivera (56455361200)
    ;
    Beslac-Bumbasirevic, Ljiljana (6506489179)
    ;
    Marjanovic, Ivan (57201599576)
    ;
    Djuric, Vanja (35361619800)
    ;
    Djordjevic, Gordana (35763715800)
    ;
    Rajic, Sonja (56516616500)
    ;
    Cvijanovic, Milan (8208649800)
    ;
    Babic, Milica (56516407400)
    ;
    Dominovic, Aleksandra (56516864600)
    ;
    Vujovic, Balsa (57021631300)
    ;
    Cukic, Mirjana (55891936800)
    ;
    Petrovic, Milutin (36969833200)
    ;
    Toncev, Gordana (6506651230)
    ;
    Komatina, Nenad (56516845100)
    ;
    Martic, Vesna (6602650915)
    ;
    Lavrnic, Dragana (6602473221)
    The aim of this study was to define features of Guillain-Barré syndrome in a large cohort of patients from three Western Balkans countries. Data from adult Guillain-Barré syndrome (GBS) cases from 2009 to 2013 were retrospectively obtained from all tertiary health care centers. During the 5-year period, 327 new cases of GBS were identified with a male to female ratio of 1.7 : 1. The most common GBS variants were demyelinating (65%) and axonal (12%). At nadir 45% of patients were chair-bound, confined to bed, or required assisted ventilation, while 5% died. The crude incidence of GBS in Serbia and Montenegro was 0.93 per 100,000 population, and age-adjusted incidence according to the world standard population was 0.86 per 100,000. Incidence was particularly high in 50- to 80-year-old men. Statistically significant seasonal variations of GBS were not observed. This study of patients with GBS in the Western Balkans allows us to prepare the health system better and to improve the management of patients. This study also opens opportunities for international collaboration and for taking part in the multinational studies on GBS. © 2015 Peripheral Nerve Society.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Clinical and epidemiological features of Guillain-Barré syndrome in the Western Balkans
    (2014)
    Peric, Stojan (35750481700)
    ;
    Milosevic, Vuk (24480195100)
    ;
    Berisavac, Ivana (6507392420)
    ;
    Stojiljkovic, Olivera (56455361200)
    ;
    Beslac-Bumbasirevic, Ljiljana (6506489179)
    ;
    Marjanovic, Ivan (57201599576)
    ;
    Djuric, Vanja (35361619800)
    ;
    Djordjevic, Gordana (35763715800)
    ;
    Rajic, Sonja (56516616500)
    ;
    Cvijanovic, Milan (8208649800)
    ;
    Babic, Milica (56516407400)
    ;
    Dominovic, Aleksandra (56516864600)
    ;
    Vujovic, Balsa (57021631300)
    ;
    Cukic, Mirjana (55891936800)
    ;
    Petrovic, Milutin (36969833200)
    ;
    Toncev, Gordana (6506651230)
    ;
    Komatina, Nenad (56516845100)
    ;
    Martic, Vesna (6602650915)
    ;
    Lavrnic, Dragana (6602473221)
    The aim of this study was to define features of Guillain-Barré syndrome in a large cohort of patients from three Western Balkans countries. Data from adult Guillain-Barré syndrome (GBS) cases from 2009 to 2013 were retrospectively obtained from all tertiary health care centers. During the 5-year period, 327 new cases of GBS were identified with a male to female ratio of 1.7 : 1. The most common GBS variants were demyelinating (65%) and axonal (12%). At nadir 45% of patients were chair-bound, confined to bed, or required assisted ventilation, while 5% died. The crude incidence of GBS in Serbia and Montenegro was 0.93 per 100,000 population, and age-adjusted incidence according to the world standard population was 0.86 per 100,000. Incidence was particularly high in 50- to 80-year-old men. Statistically significant seasonal variations of GBS were not observed. This study of patients with GBS in the Western Balkans allows us to prepare the health system better and to improve the management of patients. This study also opens opportunities for international collaboration and for taking part in the multinational studies on GBS. © 2015 Peripheral Nerve Society.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Disability and quality of life in Guillain-Barré syndrome – Longitudinal study
    (2020)
    Berisavac, Ivana (6507392420)
    ;
    Arsenijevic, Mirjana (57357620400)
    ;
    Bozovic, Ivo (57194468421)
    ;
    Mladenovic, Branka (57216509488)
    ;
    Kacar, Aleksandra (6602386522)
    ;
    Stojiljkovic Tamas, Olivera (57202112475)
    ;
    Petrovic, Milutin (36969833200)
    ;
    Stojanovic, Miroslav (55442973200)
    ;
    Vujovic, Balsa (57021631300)
    ;
    Martic, Vesna (6602650915)
    ;
    Jovanovic, Dejana (55419203900)
    ;
    Lavrnic, Dragana (6602473221)
    ;
    Basta, Ivana (8274374200)
    ;
    Peric, Stojan (35750481700)
    Longitudinal health-related quality of life (QoL) data in Guillain-Barré (GBS) patients are still scarce. We, therefore, investigated health- related QoL in GBS patients from Serbia and surrounding countries during a six-month follow-up period, and analyzed its association with patients' disability. Our study comprised 74 adult patients diagnosed with GBS from May 2017 until May 2018 in seven tertiary healthcare centers. Health-related QoL was investigated using the SF-36 questionnaire, and compared with functional disability assessed by the GBS disability scale (GDS). Tests were performed at day 14, day 28, month 3 and month 6 from disease onset. GDS and SF-36 scores improved over time (p < 0.01). GDS scores were different at all four time points, while SF-36 did not differ between day 14 and day 28. Pooled SF-36 scores (especially physical ones) correlated with pooled GDS scores, except for Bodily Pain and Role Emotional scores. We found that GDS score at day 14 was an independent predictor of GDS score at month 6 (β = +0.52, p < 0.01), while SF-36 score at day 14 was an independent predictor of SF-36 score at month 6 (β = +0.51, p < 0.01). Neurologists should look not only on disability but also on QoL in GBS patients, since these two measures provide us with important complementary items of information. © 2020 Elsevier Ltd
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Disability and quality of life in Guillain-Barré syndrome – Longitudinal study
    (2020)
    Berisavac, Ivana (6507392420)
    ;
    Arsenijevic, Mirjana (57357620400)
    ;
    Bozovic, Ivo (57194468421)
    ;
    Mladenovic, Branka (57216509488)
    ;
    Kacar, Aleksandra (6602386522)
    ;
    Stojiljkovic Tamas, Olivera (57202112475)
    ;
    Petrovic, Milutin (36969833200)
    ;
    Stojanovic, Miroslav (55442973200)
    ;
    Vujovic, Balsa (57021631300)
    ;
    Martic, Vesna (6602650915)
    ;
    Jovanovic, Dejana (55419203900)
    ;
    Lavrnic, Dragana (6602473221)
    ;
    Basta, Ivana (8274374200)
    ;
    Peric, Stojan (35750481700)
    Longitudinal health-related quality of life (QoL) data in Guillain-Barré (GBS) patients are still scarce. We, therefore, investigated health- related QoL in GBS patients from Serbia and surrounding countries during a six-month follow-up period, and analyzed its association with patients' disability. Our study comprised 74 adult patients diagnosed with GBS from May 2017 until May 2018 in seven tertiary healthcare centers. Health-related QoL was investigated using the SF-36 questionnaire, and compared with functional disability assessed by the GBS disability scale (GDS). Tests were performed at day 14, day 28, month 3 and month 6 from disease onset. GDS and SF-36 scores improved over time (p < 0.01). GDS scores were different at all four time points, while SF-36 did not differ between day 14 and day 28. Pooled SF-36 scores (especially physical ones) correlated with pooled GDS scores, except for Bodily Pain and Role Emotional scores. We found that GDS score at day 14 was an independent predictor of GDS score at month 6 (β = +0.52, p < 0.01), while SF-36 score at day 14 was an independent predictor of SF-36 score at month 6 (β = +0.51, p < 0.01). Neurologists should look not only on disability but also on QoL in GBS patients, since these two measures provide us with important complementary items of information. © 2020 Elsevier Ltd
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Self-reported autonomic dysfunction in a recovery phase of Guillain-Barré syndrome
    (2021)
    Arsenijevic, Mirjana (57357620400)
    ;
    Berisavac, Ivana (6507392420)
    ;
    Bozovic, Ivo (57194468421)
    ;
    Stojiljkovic-Tamas, Olivera (57202112475)
    ;
    Palibrk, Aleksa (57209500486)
    ;
    Lukic-Rajic, Sonja (56516616500)
    ;
    Vujovic, Balsa (57021631300)
    ;
    Peric, Stojan (35750481700)
    Objective: Autonomic dysfunction occurs in approximately two-thirds of Guillain-Barré syndrome (GBS) patients in the acute phase of the disease. Although improving over time, subclinical autonomic involvement may be present for 3–8 years after the GBS episode. The aim of this study was to determine the frequency of self-reported autonomic disorders in GBS patients three and six months after disease onset compared to healthy controls (HCs). Methods: Our study included adult patients diagnosed with GBS from May 2017 until May 2018 in seven healthcare centers (67.6 % with demyelinating and 13.6 % with axonal syubtype). Functional disability was assessed by the Guillain-Barré syndrome disability scale (GDS). Each subject filled in the Serbian version of the SCOPA-Aut questionnaire. Using GDS and SCOPA-Aut, patients were tested at month 3 (M3) (n = 71) and month 6 (M6) (n = 70) from symptom onset. Results: Dysautonomia was more common in patients with GBS compared to HCs at M3 (p < 0.01), while there was no difference at M6 (p > 0.05). Among autonomic disorders, constipation, complications to pass stool, and orthostatic hypotension were the most frequently reported. Patients with axonal variants had worse total SCOPA-Aut scores at M3 in comparison to AIDP patients (11.7 ± 10.1 vs. 6.1 ± 5.1, p < 0.05). GDS score correlated with the total SCOPA-Aut score. Conclusion: Autonomic symptoms are common in GBS patients during the recovery phase. They are more pronounced in patients with axonal forms of GBS and those with a higher degree of functional disability. © 2020 Elsevier B.V.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Three-Year Follow-Up Study in Patients with Guillain-Barré Syndrome
    (2018)
    Martic, Vesna (6602650915)
    ;
    Bozovic, Ivo (57194468421)
    ;
    Berisavac, Ivana (6507392420)
    ;
    Basta, Ivana (8274374200)
    ;
    Peric, Stojan (35750481700)
    ;
    Babic, Milica (56516407400)
    ;
    Rajic, Sonja Lukic (56516616500)
    ;
    Bjelica, Bogdan (57194461405)
    ;
    Tamas, Olivera Stojiljkovic (57202112475)
    ;
    Stojanov, Aleksandar (57194143903)
    ;
    Grunauer, Marija (57202112783)
    ;
    Cobeljic, Mina (57196349878)
    ;
    Komatina, Nenad (56516845100)
    ;
    Djuric, Vanja (35361619800)
    ;
    Petrovic, Milutin (36969833200)
    ;
    Vujovic, Balsa (57021631300)
    ;
    Kovacevic, Aleksandra Dominovic (59577737900)
    ;
    Djordjevic, Gordana (35763715800)
    ;
    Jovanovic, Dejana (55419203900)
    ;
    Stevic, Zorica (57204495472)
    A majority of patients with Guillain-Barré syndrome (GBS) have tendency of a good recovery. Our aim was to evaluate the outcome of the disease 1 and 3 years after GBS symptom onset. Methods: During 2014, GBS was diagnosed in 82 patients in seven tertiary healthcare centers. Neurological follow-up was conducted in 57 (70%) patients after 1 year, and in 54 (66%) after 3 years. Functional disability was estimated according to the GBS disability scale (GDS), with a score of 0-3 indicating mild disability and a score of 4-6 indicating severe disability during acute phase, whereas a score >1 indicated poor recovery on follow-ups. Visual analog scale was used to assess sensory symptoms and musculoskelatal pain, and Krupp's Fatigue Severity Scale was used to asses fatigue. Results: Poor functional outcome was found in 39% of GBS patients at year 1 and 30% at year 3. Paresthesias/dysesthesias were detected in 60% of patients after 1 year and 43% after 3 years. Musculoskeletal pain was present in 40% of patients at year 1 and 33% at year 3. Significant fatigue after 1 year was found in 21% of subjects and after 3 years in 7%. Parameters associated with poor functional outcome after 1 year were age >55 years (p=0.05), severe disability at admission (p<0.05), and on discharge (p<0.01). Poor functional outcome after 3 years was associated with male gender (p<0.05) and severe disability on discharge (p=0.06). Conclusion: One and even three years after GBS onset, a substantial number of patients had neurological sequelae, including functional disability, sensory symptoms, pain, and fatigue. © 2018 The Canadian Journal of Neurological Sciences Inc.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Three-Year Follow-Up Study in Patients with Guillain-Barré Syndrome
    (2018)
    Martic, Vesna (6602650915)
    ;
    Bozovic, Ivo (57194468421)
    ;
    Berisavac, Ivana (6507392420)
    ;
    Basta, Ivana (8274374200)
    ;
    Peric, Stojan (35750481700)
    ;
    Babic, Milica (56516407400)
    ;
    Rajic, Sonja Lukic (56516616500)
    ;
    Bjelica, Bogdan (57194461405)
    ;
    Tamas, Olivera Stojiljkovic (57202112475)
    ;
    Stojanov, Aleksandar (57194143903)
    ;
    Grunauer, Marija (57202112783)
    ;
    Cobeljic, Mina (57196349878)
    ;
    Komatina, Nenad (56516845100)
    ;
    Djuric, Vanja (35361619800)
    ;
    Petrovic, Milutin (36969833200)
    ;
    Vujovic, Balsa (57021631300)
    ;
    Kovacevic, Aleksandra Dominovic (59577737900)
    ;
    Djordjevic, Gordana (35763715800)
    ;
    Jovanovic, Dejana (55419203900)
    ;
    Stevic, Zorica (57204495472)
    A majority of patients with Guillain-Barré syndrome (GBS) have tendency of a good recovery. Our aim was to evaluate the outcome of the disease 1 and 3 years after GBS symptom onset. Methods: During 2014, GBS was diagnosed in 82 patients in seven tertiary healthcare centers. Neurological follow-up was conducted in 57 (70%) patients after 1 year, and in 54 (66%) after 3 years. Functional disability was estimated according to the GBS disability scale (GDS), with a score of 0-3 indicating mild disability and a score of 4-6 indicating severe disability during acute phase, whereas a score >1 indicated poor recovery on follow-ups. Visual analog scale was used to assess sensory symptoms and musculoskelatal pain, and Krupp's Fatigue Severity Scale was used to asses fatigue. Results: Poor functional outcome was found in 39% of GBS patients at year 1 and 30% at year 3. Paresthesias/dysesthesias were detected in 60% of patients after 1 year and 43% after 3 years. Musculoskeletal pain was present in 40% of patients at year 1 and 33% at year 3. Significant fatigue after 1 year was found in 21% of subjects and after 3 years in 7%. Parameters associated with poor functional outcome after 1 year were age >55 years (p=0.05), severe disability at admission (p<0.05), and on discharge (p<0.01). Poor functional outcome after 3 years was associated with male gender (p<0.05) and severe disability on discharge (p=0.06). Conclusion: One and even three years after GBS onset, a substantial number of patients had neurological sequelae, including functional disability, sensory symptoms, pain, and fatigue. © 2018 The Canadian Journal of Neurological Sciences Inc.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback